Literature DB >> 28798068

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.

Paolo Strati1, Michael J Keating1, Jan A Burger1, Susan M O'Brien1, William G Wierda1, Zeev Estrov1, Gracy Zacharian1, Alessandra Ferrajoli2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28798068      PMCID： PMC5709120          DOI： 10.3324/haematol.2017.171561

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  4 in total

1.  Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.

Authors:  Julie E Chang; Thomas Havighurst; KyungMann Kim; Jens Eickhoff; Anne M Traynor; Rachel Kirby-Slimp; Lynn M Volk; Jae Werndli; Ronald S Go; Matthias Weiss; Jules Blank; Brad S Kahl
Journal:  Br J Haematol       Date:  2016-02-23       Impact factor: 6.998

2.  Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

Authors:  Tait D Shanafelt; Alan G Ramsay; Clive S Zent; Jose F Leis; Han W Tun; Timothy G Call; Betsy LaPlant; Deborah Bowen; Adam Pettinger; Diane F Jelinek; Curtis A Hanson; Neil E Kay
Journal:  Blood       Date:  2013-03-14       Impact factor: 22.113

3.  Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.

Authors:  Paolo Strati; Michael J Keating; William G Wierda; Xavier C Badoux; Steliana Calin; James M Reuben; Susan O'Brien; Steven M Kornblau; Hagop M Kantarjian; Hui Gao; Alessandra Ferrajoli
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 4.  Targeted therapies for CLL: Practical issues with the changing treatment paradigm.

Authors:  Nitin Jain; Susan O'Brien
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250
  4 in total
  3 in total

1.  Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Authors:  Paolo Strati; Koichi Takahashi; Christine B Peterson; Michael J Keating; Philip A Thompson; Naval G Daver; Nitin Jain; Jan A Burger; Zeev Estrov; Susan M O'Brien; Hagop M Kantarjian; William G Wierda; P Andrew Futreal; Alessandra Ferrajoli
Journal:  Blood Adv       Date:  2019-05-14

2.  Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.

Authors:  Martin Gauthier; Françoise Durrieu; Elodie Martin; Michael Peres; François Vergez; Thomas Filleron; Lucie Obéric; Fontanet Bijou; Anne Quillet Mary; Loic Ysebaert
Journal:  BMC Cancer       Date:  2019-08-14       Impact factor: 4.430

3.  A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.

Authors:  Cho-Hao Lee; Po-Huang Chen; Chin Lin; Chieh-Yung Wang; Ching-Liang Ho
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.